Frontline Aspacytarabine with Venetoclax for Older/Unfit Patients with Acute Myeloid Leukemia: Preliminary Results of a Phase 1 Study

被引：0

作者：

Altman, Jessica K. ^{[1
]}

Abaza, Yasmin ^{[2
]}

Keng, Michael ^{[3
]}

Maiti, Abhishek ^{[4
]}

Koprivnikar, Jamie ^{[5
]}

Tessler, Shoshi ^{[6
]}

Blumberg, Chen ^{[6
]}

Flaishon, Liat ^{[6
]}

Ben Yakar, Ruth ^{[6
]}

机构：

[1] Northwestern Univ, Chicago, IL 60611 USA

[2] Northwestern Med, Chicago, IL USA

[3] Univ Virginia Hlth Syst, Div Hematol Oncol, Charlottesville, VA USA

[4] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA

[5] Hackensack Univ, Med Ctr, Hackensack, NJ USA

[6] BioSight Ltd, Tel Aviv, Israel

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-185694

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：4

共 50 条

[31] Pegcrisantaspase in Combination with Venetoclax for Treatment of Relapsed or Refractory Acute Myeloid Leukemia: A Phase 1 Study
Niyongere, Sandrine
Duong, Vu H.
Bollino, Dominique R.
Lapidus, Rena G.
Strovel, Erin T.
Zarrabi, Jinoos
Bah, Osman Mohamed
Philip, Sunita
Kflu, Veronica
Baer, Maria R.
Emadi, Ashkan
BLOOD, 2021, 138
[32] Results of a Phase 1 Trial Testing the Novel Combination Therapy of Venetoclax and Ruxolitinib in Relapsed/Refractory Acute Myeloid Leukemia Patients
Borate, Uma M.
Madanat, Yazan F.
Tognon, Cristina
Mishra, Shikha
Kaempf, Andy
Patel, Prapti A.
Kurtz, Stephen E.
Johnson, Kara
Vasu, Sumithira
Baker, Sharyn D.
Robinson, Bridget A.
Vu, Tania Q.
Eide, Christopher A.
Minnier, Jessica
Zhang, Yiqing
Clement, Peter
Avaylon, Sammantha
Jacob, Thomas
Cook, Rachel
Gandhi, Arpita
Leonard, Jessica T.
Hayes-Lattin, Brandon
Newell, Laura F.
Maziarz, Richard T.
Traer, Elie
Swords, Ronan T.
Tyner, Jeffrey W.
Druker, Brian J.
Saultz, Jennifer N.
BLOOD, 2023, 142
[33] Timing of response to venetoclax combination treatment in older patients with acute myeloid leukemia.
Jonas, Brian Andrew
Dinardo, Courtney Denton
Pratz, Keith
Wei, Andrew
Hong, Wan-Jen
Chyla, Brenda
Duan, Yinghui
Potluri, Jalaja
Werner, Michael
Pollyea, Daniel Aaron
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[34] Aspacytarabine (BST-236) As Monotherapy Is Safe, Well-Tolerated and Effective for the Treatment of Adults with Newly Diagnosed Acute Myeloid Leukemia Unfit for Intensive Therapy. Results of a Phase 2 Study
Altman, Jessica K.
Koprivnikar, Jamie
McCloskey, James K.
Kota, Vamsi
Keng, Michael
Bixby, Dale L.
Frankfurt, Olga
Emadi, Ashkan
Zuckerman, Tsila
Burch, Micah M.
Levy, Moshe Y.
Luger, Selina M.
Bhatnagar, Bhavana
Wolach, Ofir
Ganzel, Chezi
Percival, Mary-Beth M.
Roboz, Gail J.
Craig, Michael
Levi, Itai
Gourevitch, Anna
Flaishon, Liat
Cohen, Darrel P.
Tessler, Shoshi
Blumberg, Chen
Gengrinovitch, Stela
Ben Yakar, Ruth
Rowe, Jacob M.
BLOOD, 2021, 138
[35] Phase 1/2 Study of Venetoclax with Low-Dose Cytarabine in Treatment-Naive, Elderly Patients with Acute Myeloid Leukemia Unfit for Intensive Chemotherapy: 1-Year Outcomes
Wei, Andrew
Strickland, Stephen A.
Roboz, Gail J.
Hou, Jing-Zhou
Fiedler, Walter
Lin, Tara L.
Walter, Roland B.
Enjeti, Anoop
Chyla, Brenda
Popovic, Relja
Fakouhi, Kaffa
Shah, Pooja
Dunbar, Martin
Xu, Tu
Mabry, Mack
Hayslip, John
BLOOD, 2017, 130
[36] Cladribine, Low-Dose Cytarabine (LDAC), and Venetoclax (VEN) in Older/Unfit Acute Myeloid Leukemia (AML) Patients: A Single-Institution Experience
Yohannan, Binoy
Khan, Hina
Cervoni-Curet, Frances
Rios, Adan
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S267 - S267
[37] A Predictive Model for Early Death after Frontline Hypomethylating Agents in Elderly Unfit Acute Myeloid Leukemia Patients: Results from the Pethema Group
Ramos, Fernando
Martinez-Cuadron, David
Serrano, Josefina
Lopez-Pavia, Maria
Fuertes-Nunez, Marta
Bernal, Teresa
Rodriguez-Gutierrez, Juan Ignacio
Recio, Isabel
Garrido, Ana
Garcia, Daniel
Sossa, Claudia Lucia
Gil, Cristina
Varela, Rosario
Martinez-Sanchez, Pilar
Foncillas, Maria Angeles
Tormo, Mar
Cladera, Antonia
Esteves, Graca
Falantes, Jose F.
de la Fuente, Adolfo
Boluda, Blanca
Sanz, Miguel A.
Fernandez, Pau Montesinos
BLOOD, 2019, 134
[38] Phase II Study of Venetoclax Added to Cladribine (CLAD) and Low Dose AraC (LDAC) Alternating with 5-Azacytidine (AZA) in Older and Unfit Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)
Reville, Patrick K.
Kantarjian, Hagop
Borthakur, Gautam
Pemmaraju, Naveen
DiNardo, Courtney D.
Sasaki, Koji
Daver, Naval
Issa, Ghayas C.
Ohanian, Maro
Montalban-Bravo, Guillermo
Short, Nicholas J.
Jain, Nitin
Bhalla, Kapil N.
Jabbour, Elias J.
Ferrajoli, Alessandra
Takahashi, Koichi
Rausch, Caitlin R.
Malla, Rashmi
Marek, Kelly
Brandt, Mark
Popat, Uday R.
Andreeff, Michael
Garcia-Manero, Guillermo
Konopleva, Marina
Ravandi, Farhad
Kadia, Tapan M.
BLOOD, 2021, 138
[39] Outpatient initiation of venetoclax in patients with acute myeloid leukemia
Palmer, Shannon
Patel, Anand
Wang, Christopher
Patel, Bianka
Zeidner, Joshua
Foster, Matthew
Muluneh, Benyam
Buhlinger, Kaitlyn
JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2023, 29 (07) : 1590 - 1598
[40] Selinexor in combination with decitabine in patients with acute myeloid leukemia: results from a phase 1 study
Bhatnagar, Bhavana
Zhao, Qiuhong
Mims, Alice S.
Vasu, Sumithira
Behbehani, Gregory K.
Larkin, Karilyn
Blachly, James S.
Blum, William
Klisovic, Rebecca B.
Ruppert, Amy S.
Orwick, Shelley
Oakes, Christopher
Ranganathan, Parvathi
Byrd, John C.
Walker, Alison R.
Garzon, Ramiro
LEUKEMIA & LYMPHOMA, 2020, 61 (02) : 387 - 396

← 1 2 3 4 5 →